Ouro Medicines
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $120.0Mattributed |
|---|---|
| Latest round | series-a, $120.0M, 2025-01-08attributed |
| Founded | 2023 |
| Headquarters | San Francisco |
| Industry | bio |
| Stage | series-a |
| Website | ouromedicines.com |
Ouro Medicines is a biotechnology company developing therapeutics for immune-mediated diseases, with a clinical pipeline including candidate OM336. It targets patients living with chronic immune system disorders. The company aims to reset rather than merely suppress the underlying immune dysfunction, pursuing durable disease control.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-08 | series-a | $120.0M | nea |
Detected tech stack
Apache HTTP Server, Google Analytics, Google Tag Manager, jQuery Migrate 3.3.2, DoubleClick Floodlight, WordPress, React, PHP, MySQL, jquery 3.6.0, apache
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $120.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $120.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | ouromedicines.com, read 2026-05-07 |
| Description | self-reported | ouromedicines.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.